

AD-A046 967

TEXAS UNIV HEALTH SCIENCE CENTER AT DALLAS  
INACTIVATION OF SUBSTANCE P BY CULTURED HUMAN ENDOTHELIAL CELLS--ETC(U)  
NOV 77 A R JOHNSON, E G ERDOS  
TR-11

F/G 6/1

N00014-75-C-0807

NL

UNCLASSIFIED

1 OF 1  
AD  
A046 967



END  
DATE  
FILMED  
12-77  
DDC

AD A 0 46967

125

OFFICE OF NAVAL RESEARCH

Contract N00014-75-0807

TECHNICAL REPORT NO. 11

Inactivation of Substance P by Cultured Human  
Endothelial Cells

Prepared by

Ervin G. Erdős


For Publication in  
Substance P

Departments of Pharmacology and Internal Medicine  
University of Texas Health Science Center at Dallas  
5323 Harry Hines Boulevard  
Dallas, Texas 75235

04 November 1977

Reproduction in whole or in part is permitted for  
any purpose of the United States Government

Distribution of this report is unlimited



AD No. \_\_\_\_\_  
DDC FILE COPY



REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER Technical Report 11 ✓	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) INACTIVATION OF SUBSTANCE P BY CULTURED HUMAN ENDOTHELIAL CELLS.	5. TYPE OF REPORT & PERIOD COVERED Technical 6/1/77-12/15/78	
6. AUTHOR(s) Ervin	7. PERFORMING ORG. REPORT NUMBER	
8. AUTHOR(s) A. P. Johnson ✓ V. G. Erdos ✓	9. CONTRACT OR GRANT NUMBER(s)	
9. PERFORMING ORGANIZATION NAME AND ADDRESS Univ. TX Health Sci. Center at Dallas ✓ Dept. of Pharmacology 5323 Harry Hines Blvd., Dallas, TX	10. PROGRAM ELEMENT, TASK AND SUB-TASK NUMBERS PHS-HA-18826 NR 105-785	
11. CONTROLLING OFFICE NAME AND ADDRESS Office of Naval Research Biological & Medical Sciences Division Medical and Dental Sciences Program, Code 444 Arlington, VA	12. REPORT DATE 11/06/77	
13. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)	14. NUMBER OF PAGES 8	
15. TECHNICAL rept. 1 Jun 77 - 15 Dec 78	16. SECURITY CLASS. (of this report) Unclassified	
17. DISTRIBUTION STATEMENT (of this Report) Distribution of this document is unlimited 11 4 Nov 77 12 10p.		
18. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Block 17) 14 TR-11		
19. SUPPLEMENTARY NOTES Published in Substance P, U.S. von Euler and B. Pernow (eds.) Raven Press, NY		
20. KEY WORDS (Continue on reverse side if necessary and identify by block number) Substance P, hypotensive peptide, substance P octapeptide		
21. ABSTRACT (Continue on reverse side if necessary and identify by block number) The hypotensive peptides substance P and its octapeptide derivative are in- activated by enzymes on the surface of cultured human vascular endothelial cell		







measurement of the content of protein and DNA were given previously (10).<sup>2</sup>

SP and its octapeptide derivative, SP<sub>8</sub>, were obtained from commercial sources. The octapeptide derivative contained the 4 to 11 C-terminal amino acid sequence of the undecapeptide and was approximately half as active as SP in stimulating contraction of isolated strips of guinea pig ileum. Inactivation of SP and the octapeptide was measured by bioassay on atropinized guinea pig ileum (13). Concentrations of the peptides that stimulated submaximal contractions were used to establish a dose-response relationship. Then the spasmogenic response to peptides that had been incubated with endothelial cells or cell extracts was measured. Inactivation of the peptides by the cells was determined by following the decrease in the smooth muscle stimulating activity with the time of incubation.

When intact cell monolayers were used as a source of the enzyme, the cultures with the cells on the bottom of 250 ml flasks were washed three times with 10 ml of fresh, protein-free culture medium. Then the peptides to be tested as substrates were added directly to the culture flasks in protein-free culture medium. The flasks were agitated gently on a rocker platform that was placed inside the CO<sub>2</sub> incubator at 37°C. Samples for bioassay were withdrawn at 0 time and at regular intervals for 5 to 60 min and placed in an ice bath. All samples were assayed within 5 to 15 min after collection.

Suspended endothelial cells or cell lysates were tested for inactivation of SP or SP<sub>8</sub> in an incubation mixture that contained the peptide substrate (10<sup>-6</sup>M), 0.2 M Tris buffer (pH 7.4), and 0.2 M NaCl. When inhibitors were used, they were added to the cells in Tris buffer 15 min prior to addition of the peptide substrate. The samples were incubated at 37°C after addition of either inhibitors or substrates. For some experiments the endothelial cells were lysed by either repeated freezing and thawing, or by N<sub>2</sub> cavitation (16).

### RESULTS

Endothelial cells in tissue culture inactivated both SP and the octapeptide, SP<sub>8</sub>. Intact, undisturbed monolayers of cells cleaved the peptides at a slower rate than did the suspended or lysed cells (Table I). The rate of inactivation of SP was approximately the same regardless of the method used for detaching the cells. Thus, either treatment with trypsin or scraping of the cells yielded preparations that cleaved about 44 to 50 nmole SP per hr.

As with the angiotensin I converting enzyme (10), the SP inactivating enzyme is probably on the surface of the cells. This was indicated by the fact that there was no increase in enzymatic activity when the cells were disrupted by freezing and thawing, or by N<sub>2</sub> cavitation (Table I). However

<sup>2</sup> In order to determine whether trypsin used for detaching the cells could be bound by endothelial cells and could contribute to their enzymatic activities, we measured the uptake of <sup>125</sup>I-labeled trypsin. The cells were detached from monolayers with 0.25% trypsin containing 10<sup>5</sup> cpm/ml. They were washed in serum-containing medium and then at least three times in serum-free medium as described. The amount of radioactivity in the washes and final cell pellet was measured in a gamma radiation counter.



TABLE 1. Inactivation of SP and the SP<sub>2</sub> octapeptide by cultured human endothelial cells

Cell preparation	Treatment	No.	Substrate and Conc. (M)	Activity nmol/hr/10 <sup>6</sup> Cells
Monolayer	---	3	SP	2.4 ± 0.7
Suspended cells	trypsin (0.25%)	3	SP	1.6 ± 0.2
Suspended cells	scraped	7	SP	1.8 ± 1.0
Suspended cells	frozen-thawed	6	SP	8.0 ± 1.4
Suspended cells	N <sub>2</sub> cavitation	5	SP	4.7 ± 1.4
Suspended cells	trypsin (0.25%)	5	octapeptide	4.4 ± 1.1
Cells were incubated at 37°C and pH 7.4 with substrates. Samples assayed on guinea pig serum.				

in contrast to the effect on the substrate. The effect of the substrate on the activity of the SP is shown in Table 1. The activity of the SP was significantly reduced by treatment with trypsin (0.25%), scraped cells, frozen-thawed cells, and N<sub>2</sub> cavitation. The activity of the SP was also reduced by treatment with trypsin (0.25%) and octapeptide. The activity of the SP was not significantly reduced by treatment with trypsin (0.25%) and octapeptide.




FIG. 1. Inactivation of SP and the SP<sub>2</sub> octapeptide by cultured human endothelial cells. The activity of the SP and the octapeptide was measured in the presence of 10<sup>6</sup> cells. The activity of the SP was significantly reduced by treatment with trypsin (0.25%), scraped cells, frozen-thawed cells, and N<sub>2</sub> cavitation. The activity of the SP was also reduced by treatment with trypsin (0.25%) and octapeptide. The activity of the SP was not significantly reduced by treatment with trypsin (0.25%) and octapeptide.



TABLE 2. Inhibition of the enzyme(s) in endothelial cells that inactivate SP

Inhibitor	Conc	Substrate	No.	% Inhibition
Soybean trypsin	800 $\mu$ g/ml	SP ( $10^{-6}$ M)	8	88
Trasylol*	1,000 $\mu$ g/ml	"	4	85
<i>o</i> -phenanthroline	$10^{-3}$ M	"	6	0
Leucyl-methionine amide	$10^{-4}$ M	"	4	41
TAME	$10^{-4}$ M	"	5	63
DFP	$10^{-4}$ M	"	4	83

in contrast to the effect on the angiotensin I converting enzyme (10), freezing and thawing of the cells did not decrease activity of the SP inactivating enzyme.<sup>2</sup>

Various inhibitors were used in an attempt to characterize the enzymes that cleaved SP and the octapeptide. The results of experiments with enzyme inhibitors of the inactivation of SP are summarized in Table 2. Typical experiments in which inactivation of SP was measured both with and without inhibitors are shown in Figs. 1 and 2. Of the several enzyme inhibitors tested, *o*-phenanthroline, a metal chelating agent that inhibits peptidases,




FIG. 1. Inactivation of SP by endothelial cells. Suspended cells ( $0.9 \times 10^6$ ) were incubated with buffer alone or with soybean trypsin inhibitor (SBTI) or di-isopropylfluorophosphate (DFP) for 15 min at  $37^\circ\text{C}$ . Concentrations of inhibitors given in Table 2. SP was added ( $10^{-6}$ M) and the activity measured at 0 to 10 min by bioassay on guinea pig ileum. The amount of peptide remaining in the reaction mixture is given on the ordinate and time on the abscissa.

\*When labeled trypsin was used to detach endothelial cells, approximately 1% of the label (equivalent to 2.5  $\mu$ g of trypsin) was retained by the cells. It was not determined whether this enzyme remained active after it was associated with the cells. However, in other experiments, cells first scraped from the monolayer and then incubated with trypsin were not more active in cleaving SP than cells scraped and only washed.






FIG. 2. Inactivation of SP by endothelial cells. Suspended cells ( $1.5 \times 10^5$ ) were incubated with buffer alone or with Trasylol<sup>®</sup> or *o*-phenanthroline for 15 min at 37°C. (Concentrations given in Table 2.) SP was added ( $10^{-6}$ M) and activity was measured by bioassay on guinea pig ileum.

did not block the inactivation of SP by endothelial cells. DFP, an inhibitor of serine proteases, and inhibitors of trypsin-like enzymes, such as Trasylol<sup>®</sup> (aprotinin) and soybean trypsin inhibitor blocked the inactivation of SP. Alpha-N-tosylarginine methyl ester (TAME), a substrate of trypsin, inhibited inactivation by 63% at a final concentration of  $10^{-2}$ M. The dipeptide, leucyl-methionylamide, was a more potent inhibitor because it inhibited at a final concentration of  $10^{-4}$ M.

The inhibition pattern of the inactivation of the octapeptide was more complex. Both metal chelating agents, EDTA and *o*-phenanthroline, as well as the protease inhibitors, soybean trypsin inhibitor, Trasylol<sup>®</sup>, and DFP prevented loss of spasmogenic action of SP<sub>8</sub> during incubation with the endothelial cells (Table 3). The decline in activity on the guinea pig

TABLE 3. Inhibition of the enzyme(s) in endothelial cells that inactivate the octapeptide (SP<sub>8</sub>)

Inhibitor	Conc.	Substrate	No.	% Inhibition
Soybean trypsin	600 $\mu$ g/ml	Octapeptide ( $10^{-6}$ M)	2	58
Trasylol <sup>®</sup>	1,000 u/ml	"	4	75
EDTA	$5 \times 10^{-3}$ M	"	2	61
<i>o</i> -phenanthroline	$10^{-3}$ M	"	5	64
DFP	$10^{-3}$ M	"	4	68

Cells were suspended, incubated with inhibitors for 15 min at 37°C prior to addition of substrate. Assayed on guinea pig ileum.






FIG. 3. Inactivation of SP<sub>1-9</sub> by endothelial cells. Suspended cells ( $1.5 \times 10^6$ ) were incubated with buffer alone or with inhibitors (concentrations given in Table 3) for 15 min at 37°C. SP<sub>1-9</sub> was added ( $10^{-6}$ M) and its activity was measured by bioassay on guinea pig ileum.

ileum during incubation with cells or cells and two different inhibitors is shown in Fig. 3.

#### DISCUSSION

Although SP is among the most active endogenous peptides, its enzymatic metabolism has not been investigated in detail. Pernow (14) indicated that chymotrypsin inactivates SP much faster than trypsin does when inactivation was measured by bioassay on the guinea pig ileum. He also noted that extracts from many tissues contained proteolytic inactivators of SP. Recently, Benuck and Marks (3) described a partially purified enzyme from rat brain that cleaved SP at two internal bonds and inactivated the peptide with respect to smooth muscle stimulating action.

In another study of enzymes in cultured human endothelial cells, we found that either monolayers or suspended cells could cleave vasoactive peptides such as angiotensin I and bradykinin. This activity was attributed to the angiotensin I converting enzyme, or kininase II (9,10). However, the enzyme was much more active when the cells were suspended than when they were in a monolayer. This increase in activity with suspension may be due to an increase in the surface area of the suspended cells and to an increase in the rate of interaction between substrate and the surface-bound enzyme.

We found that cultured human endothelial cells also inactivate SP, and that a similar increase in activity occurred when the cells were suspended from monolayers into separated cells. Although endothelial cells treated



with  $^{125}\text{I}$ -labeled trypsin took up the label, inactivation of SP cannot be due to contamination with exogenous trypsin. First, cells in monolayers were able to inactivate SP and  $\text{SP}_8$ . Second, the cells suspended by scraping were as active as trypsin-suspended cells in cleavage of SP. Finally, trypsin treatment of scraped cells did not enhance the inactivation of SP. This observation supports reports of others (4,14) that SP is resistant to degradation by trypsin.

The initial site of cleavage has not been determined. If the endothelial enzyme is a tryptic enzyme similar to plasmin or thrombin, it might attack the  $\text{Lys}^1\text{-Pro}^2$  bond and release  $\text{SP}_8$  which, under our conditions of assay, had less smooth muscle-stimulating activity than SP. However, the protease might cleave another peptide bond that is not adjacent to a basic amino acid. This was shown in experiments in which hydrolysis of  $\text{SP}_8$  was partially inhibited by protease inhibitors. Anastasi et al (1) observed that trypsin cleaves anomalously such a bond in physalaemin, a peptide that is structurally similar to SP.

Possibly, the enzyme that cleaves SP and  $\text{SP}_8$  is a peptidase with a heavy metal cofactor, since it is inhibited both by *o*-phenanthroline and by EDTA. This enzyme might attack  $\text{SP}_8$  at the N-terminal end and cleave the  $\text{Pro}^4\text{-Gln}^5$  bond. These speculations will have to be confirmed by chemical assay of the products cleaved from the peptides, since only very limited information can be obtained from bioassay.

The importance of cleavage of SP by an enzyme bound to the surface of endothelial cells seems obvious. SP is a very potent hypotensive agent, and its release into blood would bring it into immediate contact with the vascular endothelium. Since the vasodilator actions of SP varies according to the particular vascular bed and the animal species tested (*this volume*), these differences may reflect, in part, differences in rates of inactivation of the peptide. Although peptide fragments of SP have biological activities (*this volume*), some actions may require the intact undecapeptide. For example, the sialogogue action (11,15) and the release of histamine from mast cells (8) are two of these. Histamine release by SP presumably depends upon the presence of basic amino acids in the peptide sequence. Conversion of SP to the octapeptide,  $\text{SP}_8$ , by removal of the N-terminal tripeptide removes both the arginine and lysine that convey a net positive charge to the undecapeptide. Thus,  $\text{SP}_8$  might have a different action on various target cells. The octapeptide can be degraded by enzymes in endothelium and other tissues, and its actions would probably be brief and limited to a specific environment, such as the vascular smooth muscle of selected vascular beds.

We cannot delineate the actions of SP and its metabolic products *in vivo*. However, our experiments show that human endothelial cells grown in tissue culture can inactivate both SP and the octapeptide derivative,  $\text{SP}_8$ , and suggest that inactivation by endothelium contributes to the termination of the action of SP *in vivo*.



## ACKNOWLEDGMENTS

We would like to thank Mrs. Nit Ton Boyden for technical assistance in this study. This work was supported by the following grants: HL 18826 (NIH), HL 14187 (NIH), HL 16320 (NIH), and contract ONR N00014-75-C-0807.

## REFERENCES

1. Anastasi, A., Ersparmer, V., and Cei, J. M. (1964): Isolation and amino acid sequence of physalaemin, the main active polypeptide of the skin of *Physalaemus fuscimaculatus*. *Archiv. Biochem. Biophys.*, 108:341-348.
2. Bakhle, Y. S., and Vane, J. R. (1974): Pharmacokinetic function of the pulmonary circulation. *Physiol. Rev.*, 54:1007-1045.
3. Benuck, M., and Marks, N. (1975): Enzymatic inactivation of substance P by a partially purified enzyme from rat brain. *Biochem. Biophys. Res. Commun.*, 65:153-160.
4. Chang, M. M., and Leeman, S. E. (1971): Amino-acid sequence of substance P. *Nature [New Biol.]*, 232:86-87.
5. Erdös, E. G. (1976): Conversion of angiotensin I to angiotensin II. *Am. J. Med.*, 60:746-759.
6. Gimbrone, M. A., Cotran, R. S., and Folkman, J. (1974): Human vascular endothelial cells in culture. Growth and DNA synthesis. *J. Cell Biol.*, 60:673-684.
7. Jaffe, E. A., Nachman, R. L., Becker, C. G., and Minick, R. (1973): Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. *J. Clin. Invest.*, 52:2745-2756.
8. Johnson, A. R., and Erdös, E. G. (1973): Release of histamine from mast cells by vasoactive peptides. *Proc. Soc. Exp. Biol. Med.*, 142:1252-1256.
9. Johnson, A. R., and Erdös, E. G. (1975): Angiotensin I converting enzyme in human endothelial cells. *Circulation*, 52:[Suppl. II], 59.
10. Johnson, A. R., and Erdös, E. G. (1976): Metabolism of vasoactive peptides by endothelial cells in culture: Angiotensin I converting enzyme (kininase II) and angiotensinase. *J. Clin. Invest.*, (in press).
11. Lembeck, F., and Starke, K. (1968): Substanz P und Speichelsekretion. *N.S. Arch. Pharmakol. Exp. Path.*, 259:375-385.
12. Lewis, L. J., Hoak, J. C., Maca, R. D., and Fry, G. L. (1973): Replication of human endothelial cells in culture. *Science*, 181:453-454.
13. Pernow, B. (1953): Studies on substance P. Purification, occurrence and biological actions. *Acta Physiol. Scand.*, Suppl., 29:105.
14. Pernow, B. (1955): Inactivation of substance P by proteolytic enzymes. *Acta Physiol. Scand.*, 34:295-302.
15. Vogler, K., Haefely, W., Hürlimann, A., Studer, R. O., Lergier, W., Strässle, R., and Bernini, K. H. (1963): A new purification procedure and biological properties of Substance P. *Ann. N.Y. Acad. Sci.*, 104:378-390.
16. Wallach, D. F., and Kamat, V. B. (1966): Preparation of plasma-membrane fragments from mouse ascites tumor cells. *Methods Enzymol.*, 8:164-172.